BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 29742289)

  • 1. The genetic and molecular pathogenesis of myelodysplastic syndromes.
    Shallis RM; Ahmad R; Zeidan AM
    Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The functional mechanisms of mutations in myelodysplastic syndrome.
    Nagata Y; Maciejewski JP
    Leukemia; 2019 Dec; 33(12):2779-2794. PubMed ID: 31673113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
    Lee JH; List A; Sallman DA
    Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
    Sallman DA; Tanaka TN; List A; Bejar R
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
    Bidet A; Dulucq S; Smol T; Marceau-Renaut A; Morisset S; Coiteux V; Noël-Walter MP; Nicolini FE; Tigaud I; Luquet I; Struski S; Gaillard B; Penther D; Tondeur S; Nadal N; Hermet E; Véronèse L; Réa D; Gervais C; Theisen O; Terré C; Cony-Makhoul P; Lefebvre C; Gaillard JB; Radford I; Vervaeke AL; Barin C; Chapiro E; Nguyen-Khac F; Etienne G; Preudhomme C; Mahon FX; Roche-Lestienne C;
    Haematologica; 2019 Jun; 104(6):1150-1155. PubMed ID: 30573507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of MDS.
    Ogawa S
    Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
    Caponetti GC; Bagg A
    Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the molecular pathophysiology of myelodysplastic syndromes.
    Bejar R; Levine R; Ebert BL
    J Clin Oncol; 2011 Feb; 29(5):504-15. PubMed ID: 21220588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
    Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
    Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
    Matos A; Magalhães SMM; Rauh MJ
    Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
    Rotter LK; Shimony S; Ling K; Chen E; Shallis RM; Zeidan AM; Stahl M
    Cancer J; 2023 May-Jun 01; 29(3):111-121. PubMed ID: 37195766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
    Kennedy JA; Ebert BL
    J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
    Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
    Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.